Media stories about Vermillion (NASDAQ:VRML) have trended somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vermillion earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave headlines about the company an impact score of 41.7495565760686 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Several brokerages have recently commented on VRML. ValuEngine lowered Vermillion from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Canaccord Genuity reissued a “buy” rating and set a $1.75 price target (down previously from $2.50) on shares of Vermillion in a research note on Wednesday, August 30th.

Shares of Vermillion (NASDAQ:VRML) traded up 4.14% during midday trading on Thursday, hitting $1.51. The stock had a trading volume of 27,176 shares. Vermillion has a one year low of $0.76 and a one year high of $2.85. The company’s market cap is $84.81 million. The firm has a 50 day moving average of $1.47 and a 200-day moving average of $1.64.

Vermillion (NASDAQ:VRML) last posted its quarterly earnings data on Wednesday, August 9th. The company reported ($0.04) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.04). Vermillion had a negative net margin of 372.05% and a negative return on equity of 215.26%. The business had revenue of $0.90 million for the quarter. On average, analysts forecast that Vermillion will post ($0.16) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Vermillion (VRML) Receives Daily Media Sentiment Score of 0.05” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at

Vermillion Company Profile

Vermillion, Inc is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery.

Insider Buying and Selling by Quarter for Vermillion (NASDAQ:VRML)

Receive News & Stock Ratings for Vermillion Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion Inc. and related stocks with our FREE daily email newsletter.